皮调节素
安非雷古林
西妥昔单抗
肿瘤科
医学
内科学
头颈部鳞状细胞癌
头颈部癌
化疗
放化疗
放射治疗
癌症
癌症研究
结直肠癌
表皮生长因子受体
作者
Yasunao Kogashiwa,Hitoshi Inoue,Kiyomi Kuba,Ryuichiro Araki,Masanori Yasuda,Mitsuhiko Nakahira,Masashi Sugasawa
出处
期刊:Head & neck
[Wiley]
日期:2018-10-10
卷期号:40 (11): 2424-2431
被引量:23
摘要
BACKGROUND: Cetuximab combined with chemoradiotherapy chemotherapy is the standard therapy for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). However, survival benefit is limited. The purpose of this study was to investigate the expression of epiregulin (EREG) and amphiregulin (AREG), as predictive prognostic markers for the efficacy of cetuximab combined with chemotherapy in R/M HNSCC. METHODS: We conducted a retrospective analysis of 37 patients diagnosed with R/M HNSCC. Tumor samples were analyzed for EREG and AREG mRNA gene expression, and clinical outcomes evaluated. RESULTS: Values of EREG and AREG were associated with significantly longer overall survival (OS) (P = .03 and P = .01, respectively), as well as progression-free survival (PFS) (P = .04 and P = .04, respectively). Multivariate analysis revealed that AREG expression was significantly associated with OS and PFS. CONCLUSIONS: Patients with recurrent/metastatic HNSCC with higher EREG and AREG gene expression appear to benefit more from cetuximab combined with chemoradiotherapy chemotherapy than those with lower expression.
科研通智能强力驱动
Strongly Powered by AbleSci AI